You can buy or sell NBSE and other stocks, options, ETFs, and crypto commission-free!
NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. Read More The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
52 Week High
52 Week Low
— per share
Expected May 13, After Hours